CliffBio
small molecule

ZELVYSIA

SAPROPTERIN DIHYDROCHLORIDE

Loss of exclusivity—loss of exclusivity
CompanyAUCTA →See this company's full patent-cliff portfolio

Drug detail

Brand nameZELVYSIA
Active ingredientSAPROPTERIN DIHYDROCHLORIDE
Strength100MG/PACKET
Dosage formPOWDER
RouteORAL
ModalitySmall molecule
FDA approvalApril 2025
Marketing statusRX

More from AUCTA

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

ZELVYSIA patent cliff — loss of exclusivity — | CliffBio